Delivery of novel macromolecular drugs against HIV-1

Bibliography

• DE CLERCQ E: Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. (1995) 38:2491–2517.
   PubMed Web of Science ®Google Scholar
• POWDERLY WG: Current approaches to treatment for HIV-1 infection. J Neurovirol (2000) 6\(Suppl. 1):S8–S13.
   Google Scholar
• BONFANTI P, CAPETTI A, RIZZARDINI G: HIV disease treatment in the era of HAART. Biomed. Pharmacother. (1999) 53:93–105.
   PubMed Web of Science ®Google Scholar
• MONTANER JSG, MONTESSORI V, HARRIGAN R, O'SHAUGHNESSY M, HOGG R: Antiretroviral therapy: the state of the art'. Biomed. Pharmacother. (1999) 53:63–72.
   PubMedGoogle Scholar
• TOMASSELLI AG, HEINRIKSON RL: Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochim. Biophys. Acta (2000) 1477:189–214.
   PubMed Web of Science ®Google Scholar
• CONWAY B, ROUTY J-P, SEKALY R-P: Combination therapy for HIV: towards long term control of disease progression. Expert Opin. Invest. Drugs (1998) 7:941–961.
   PubMedGoogle Scholar
• HANNA GJ, D'AQUILA RT: Antiretroviral drug resistance in HIV-1. Cun: Infect. Dis. Rep. (1999) 1:289–297.
   Google Scholar
• ERICE A, BALFOUR HHJR: Resistance of human immunodeficiency virus type 1 to antiretroviral agents: A review. Clin. Infect. Dis. (1994) 18:149–156.
   PubMed Web of Science ®Google Scholar
• BODEN D, MARKOWITZ M: Resistance to human immunodeficiency virus Type 1 protease inhibitors. Antimicrob. Agents Chemother. (1998) 42:2775–2783.
   PubMed Web of Science ®Google Scholar
• BUSHMAN F, LANDAU NR, EMINI EA: New developments in the biology and treatment of HIV. Proc. Nati Acad. Sci. USA (1998) 95:11041–11042.
   PubMed Web of Science ®Google Scholar
• CHESNEY MA, ICKOVICS J, HECHT FM, SIKIPA G, RABKIN J: Adherence: a necessity for successful HIV combination therapy. AIDS (1999) 13(Suppl. A):5271–S278.
   Google Scholar
• DESCAMPS D, FLANDRE E CALVEZ V et al.: Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur la SIDA 072) study team. JAMA (2000) 283:205–211.
   Google Scholar
• DLIZGLINES N: Treatment of human immunodeficiency virus, Mycobacterium avium and Mycobacterium tuberculosis infections by liposome-encapsulated drugs. In: Medical Applications of Lioosomej. Lasic DD, Papahadjopoulos D (Eds.), Elsevier Science By., Amsterdam (1998):189–219.
   Google Scholar
• ORR RIVI, O'NEILL CF: Patent review: Therapeutic applications for antisense oligonucleotides. Curr. Opin. Mal. Ther. (2000) 2:325–331.
   PubMed Web of Science ®Google Scholar
• THIERRY AR, TAKLE GB. Liposomes as a delivery system for antisense and ribozyme compounds. In: Delivery Strategies for Antisense Oligarrucleatide Therapeutics. Akhtar S (Ed.), CRC Press, Boca Raton, FL, (1995):199–221.
   Google Scholar
• MATSUKURA M, ZON G, SHINOZUKA K et al.: Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (artnrs) in chronically infected cells. Proc. Natl. Acad. Sci. USA (1989) 86:4244–4248.
   PubMed Web of Science ®Google Scholar
• •The authors showed that a phosphorothioate oligodeoxynucleotide complementary to the initiation sequence of HIV-1 rev had a significant inhibitory effect on the production of several viral proteins in chronically HIV-1-infected T-cells and drastically reduced the unspliced (genomi0 viral mRNA transcripts, with relative sparing of smaller (spliced) transcripts. This inhibitory effect was shown to be sequence-specific and dependent on the chemical modification of the phosphodiester linkage. This oligonudeotide developed by these investigators has also been used in subsequent delivery studies [57,68].
   Google Scholar
• STEIN CA, NECKERS LM, NAIR BC, MUMBAUER S, HOKE G, PAL R: Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4. j Acquir: Immune Defic. Synth: Hum. Retrovirol. (1991) 4:686–693.
   Google Scholar
• LISZIEWICZ J, SUN D, KLOTMAN M, AGRAWAL S, ZAMECNIK P, GALLO R: Specific inhibition of human immunodeficiency virus Type 1 replication by antisense oligonucleotides: An in vitro model for treatment. Proc. Natl. Acad. Li. USA (1992) 89:11209–11213.
   PubMed Web of Science ®Google Scholar
• LISZIEWICZ J, SUN D, WEICHOLD FF et al.: Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus Type 1 in human peripheral blood cells. Proc. Nati Acad. Li. USA (1994) 91:7942–7946.
   PubMed Web of Science ®Google Scholar
• WEICHOLD F1 LISZIEWICZ J, ZEMAN RA et al.: Antisense phosphorothioate oligodeoxynucleotides alter HIV Type 1 replication in cultured human macrophages and peripheral blood mononuclear cells. AIDS Res. Hum. Retroviruses (1995) 11:863–868.
   Google Scholar
• WAGNER RW, FLANAGAN WM: Antisense technology and prospects for therapy of viral infections and cancer. Mal. Med. Today (1997) 3:31–38.
   PubMedGoogle Scholar
• MATTEUCCI MD, WAGNER RW: In pursuit of antisense. Nature (1996) 384(Suppl.):20–22.
   Google Scholar
• DOZGONES N, PRETZER E, SIM0ES S et al.: Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells. Mai Membr. Biol (1999) 16:111–118.
   Google Scholar
• YAMAGUCHI K, PAPP B, ZHANG DZ, ALI AN, AGRAWAL S, BYRN RA: The multiple inhibitory mechanisms of GEM 91(R), a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus Type 1. AIDS Res. Hum. Retroviruses (1997) 13:545–554.
   PubMed Web of Science ®Google Scholar
• COOK PD:. Antisense medicinal chemistry. In: Antisense Research and Application. Crooke ST (Ed.), Springer-Verlag, Berlin (1998):51–92.
   Google Scholar
• AKHTAR S, HUGHES MD, KHAN A et al.: The delivery of antisense therapeutics. Adv. Drug Deify. Rev (2000) 44:3–21.
   PubMed Web of Science ®Google Scholar
• GARCIA-CHAUMONT C, SEKSEK 0, GRZYBOWSKA J, BOROWSKI E, BOLARD J: Delivery systems for antisense oligonucleotides. Pharmacol. Ther. (2000) 87:255–277.
   PubMed Web of Science ®Google Scholar
• BANGHAM AD: Surrogate cells or Trojan horses. The discovery of liposomes. BioEssays (1995) 17:1081–1088.
   PubMed Web of Science ®Google Scholar
• LASIC D, MARTIN F: Stealth Liposomes. CRC Press, Boca Raton, Florida, USA (Eds) (1995): 1–289.
   Google Scholar
• LASIC DD, PAPAHADJOPOULOS D: In: Medical Applications of Lioosomes. Elsevier Science B.V., Amsterdam (Eds) (1998): 1–7.
   Google Scholar
• BAKKER-WOUDENBERG IAJM, VAN ETTEN EWM: Long-circulating liposomes containing antibacterial and antifungal agents. In: Medical Applications of Liposomes. Lasic DD, Papahadjopoulos D (Eds.), Elsevier Science B.V., Amsterdam (1998):181–188.
   Google Scholar
• GOREN D, GABIZON A: Pharmacologic advantages of anthracyclines encapsulated in poly-ethylene-glycol coated Stealth liposomes. In: Medical Applications of Liposomes. Lasic DD, Papahadjopoulos D (Eds.), Elsevier Science B.V., Amsterdam (1998):259–274.
   Google Scholar
• THIERRY AR, DRITSCHILO A: Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res. (1992) 20:5691–5698.
   PubMed Web of Science ®Google Scholar
• TART AM, TUCKER SD, DEISSEROTH A, LOPEZ-BERESTEIN G: Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood (1994) 84:601–607.
   PubMed Web of Science ®Google Scholar
• TART A, KHODADADIAN M, ELLERSON D, DEISSEROTH A, LOPEZ-BERESTEIN G: Liposome' delivery of oligodeoxynucleotides. Leuk. Lymphoma (1996) 21:93–97.
   PubMedGoogle Scholar
• LEONETTI J-P, MACHY P, DEGOLS G,LEBLEU B, LESERMAN L: Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication. Proc. Nati Acad. Li. USA (1990) 87:2448–2451.
   PubMed Web of Science ®Google Scholar
• STEVENSON M, IVERSEN PL: Inhibition of human immunodeficiency virus Type 1-mediated cytopathic effects by poly(L-lysine)-conjugated synthetic antisense oligonucleotides. I Gen. Viral. (1989) 70:2673–2682.
   PubMed Web of Science ®Google Scholar
• BENNETT FC, CHIANG MY, CHAN HC, SHOEMAKER JEE, MIRABELLI CK: Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacal. (1992) 41:1023–1033.
   PubMed Web of Science ®Google Scholar
• LAPPALAINEN K, URTTI A, SODERLING E, JAASKELAINEN I, SYRJANEN K, SYRJANEN S: Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. Biochim. Biophys. Acta (1994) 1196:201–208.
   PubMed Web of Science ®Google Scholar
• LAPPALAINEN K, PIRILA L, JAASKELAINEN I, SYRJANEN K, SYRJANEN S: Effects of liposomal antisense oligonucleotides on mRNA and protein levels of the HPV 16 E7 oncogene. Anti-Cancer Res. (1998) 16:2485–2492.
   Web of Science ®Google Scholar
• KABANOV AV, VINOGRADOV SV, SUZDALTSEVA YG, ALAKHOV VY: Water-soluble block polycations as carriers for oligonucleotide delivery. Bioconjug. Chem. (1995) 6:639–643.
   PubMed Web of Science ®Google Scholar
• HUGHES JA, ARONSOHN Al, AVRUTSKAYA AV, JULIANO RL: Evaluation of adjuvants that enhance the effectiveness of antisense oligodeoxynucleotides. Pharm. Res. (1996) 13:404–410.
   PubMed Web of Science ®Google Scholar
• ZELPHATI 0, SZOKA FC Jr.: Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm. Res. (1996) 13:1367–1372.
   Google Scholar
• ZELPHATI 0, SZOKA FC Jr.: Mechanism of oligonucleotide release from cationic liposomes. Proc. Nati Acad. Sd. USA (1996) 93:11493–11498.
   Google Scholar
• ROPERT C, LAVIGNON M, DUBERNET C, COUVREUR P, MALVY C: Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. Biochem. Biophys. Res. Commun. (1992) 183:879–885.
   PubMed Web of Science ®Google Scholar
• ••The first paper showing that pH-sensitiveliposomes can enhance the antiviral effect of antisense oligonucleotides.
   Google Scholar
• DOZGLINIES N, FLASHER D, PRETZER E et al.: Liposome-mediated therapy of human immunodeficiency virus type-1 and mycobacterium infections. j Liposome Res. (1995) 5:669–691.
   Google Scholar
• DE OLIVEIRA MC, FATTAL E, COUVREUR P et al.: pH-Sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in quasi-anhydrous samples. Biochim. Biophys. Acta Bio-Memb. (1998) 1372:301–310.
   PubMed Web of Science ®Google Scholar
• DE OLIVEIRA MC, ROSILIO V, LESIEUR P et al.: pH-sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in excess water. Biophys. Chem. (2000) 87:127–137.
   PubMed Web of Science ®Google Scholar
• RENNEISEN K, LESERMAN L, MATTHES E, SCHRODER HC, MOLLER WEG: Inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-targeted liposomes containing antisense RNA to the ertvregion. Bia Chem. (1990) 265:16337–16342.
   PubMed Web of Science ®Google Scholar
• ZELPHATI 0, ZON G, LESERMAN L: Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. Antisense Res. Dev. (1993) 3:323–338.
   PubMedGoogle Scholar
• ••The authors provided evidence that the efficacy and specificity of antisense oligonuceotides can be strongly enhanced upon encapsulation in liposomes targeted to cells expressing HLA class I molecules.
   Google Scholar
• ZELPHATI 0, WAGNER E, LESERMAN L: Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes. Antiviral Res. (1994) 25:13–25.
   PubMed Web of Science ®Google Scholar
• ZELPHATI 0, IMBACH J-L, SIGNORET N, ZON G, RAYNER B, LESERMAN L: Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res. (1994) 22:4307–4314.
   PubMed Web of Science ®Google Scholar
• SIMOES S, PIRES P, DOZGLINES N, PEDROSO DE LIMA MC: Cationic liposomes as gene transfer vectors: Barriers to successful application in gene therapy. Cun: Opin. Mol. Ther. (1999) 1:147–157.
   PubMed Web of Science ®Google Scholar
• FELGNER PL, GADEK TR, HOLM M et al.: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Frac Natl. Acad. Sci. USA (1987) 84:7413–7417.
   PubMed Web of Science ®Google Scholar
• ROJANASAKUL Y: Antisense oligonucleotide therapeutics: drug delivery and targeting. Adv. Drug Deify. Rev (1996) 18:115–131.
   Web of Science ®Google Scholar
• ANAZODO MI, WAINBERG MA, FRIESEN AD, WRIGHT JA: Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus Type 1 genome. Viral. (1995) 69:1794–1801.
   PubMed Web of Science ®Google Scholar
• LAVIGNE C, THIERRY AR: Enhanced antisense inhibition of human immunodeficiency virus Type 1 in cell cultures by DLS delivery system. Biochem. Biophys. Res. Commun. (1997) 237:566–571.
   PubMed Web of Science ®Google Scholar
• ••In this report, a novel cationic lipidicformulation, designated DLS liposomes, is described. The liposome-oligonucleotide complexes exhibited a homogeneous size distribution and high entrapment, and had a remarkable anti-HIV-1 effect even at sub-nanomolar concentrations of the antisense oligonucleotide. If verified, this system may be considered the most efficient lipid-based carrier for antisense macromolecule delivery.
   Google Scholar
• PLANK C, MECHTLER K, SZOKA FCJR, WAGNER E: Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum. Gene Ther. (1996) 7:1437–1446.
   PubMed Web of Science ®Google Scholar
• ZELPHATI 0, UYECHI LS, BARRON LG, SZOKA FCJR: Effect of serum components on the physico-chemical properties of cationic lipiclioligonucleotide complexes and on their interactions with cells. Biochim. Biophys. Acta (1998) 1390:119–133.
   PubMed Web of Science ®Google Scholar
• •This report shows that serum components can decrease oligonucleotide delivery into cells by changing the physico-chemical properties of cationic lipid/oligonucleotide complexes and by dissociating the complexes. Based on the finding that bovine serum albumin can protect the complex against dissociation from certain polyanions present in serum, the authors suggest the possibility that albumin can be used to coat pre-formed cationic complexes to protect it from interaction with other species.
   Google Scholar
• LITZINGER DC, BROWN JM, WALA I et al.: Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta (1996) 1281:139–149.
   PubMed Web of Science ®Google Scholar
• MEYER 0, KIRPOTIN D, HONG K et al.: Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. _J. Biol. Chem. (1998) 273:15621–15627.
   Google Scholar
• •This work describes the potential of using liposomes composed of a cationic lipid, a neutral lipid and a phospholipid derivative of PEG to prepare complexes with oligonucleotides. Modification with PEG-PE not only increased the particle stability of the complexes but also facilitated high entrapment of oligonucleotides, resulting in neutral or negatively charged particles. Conjugation of antibody fragments recognising the HER2 receptor to the complexes mediated targeting of the drug to specific tissues, resulting in enhanced biological activity.
   Google Scholar
• CONNOR J, HUANG L: Efficient cytoplasmic delivery of a fluorescent dye by pH-sensitive liposomes. I Cell Biol. (1985) 101:582–589.
   Web of Science ®Google Scholar
• STRAUBINGER RIVI, DOZGLINES N, PAPAHADJOPOULOS D: pH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Lett. (1985) 179:148–154.
   PubMed Web of Science ®Google Scholar
• DOZGONES N, STRAUBINGER RM, BALDWIN PA, PAPAHADJOPOULOS D: pH-Sensitive liposomes: Introduction of foreign substances into cells. In: Membrane Fusion. WILSCHUT J, HOEKSTRA D (Eds.) Marcel Dekker, Inc., New York (1990:713–730.
   Google Scholar
• TORCHILIN VP ZHOU F, HUANG L: pH-Sensitive liposomes. J. Liposome Res. (1993) 3:201–255.
   Google Scholar
• CHU C-J, DIJKSTRA J, LAI M-Z, HONG K, SZOKA FC: Efficiency of cytoplasmic delivery by pH-sensitive liposomes to cells in culture. Pharm. Res. (1990) 7:824–834.
   PubMed Web of Science ®Google Scholar
• STRAUBINGER RM: pH-sensitive liposomes for delivery of macromolecules into cytoplasm of cultured cells. Methods Enzymol. (1993) 221:361–376.
   PubMed Web of Science ®Google Scholar
• DOZGONES N, SIM0ES S, SLEPUSHKIN V et al: Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes. Nucleosides Nucleotides Nucleic Acid (2001) 20:515–523.
   PubMed Web of Science ®Google Scholar
• •The authors show the utility of pH-sensitive and sterically stabilised pH-sensitive liposomes in the delivery of several macromolecular drugs to HIV-1-infected macrophages.
   Google Scholar
• SELVAM MP, BUCK SM, BLAY RA, MAYNER RE, MIED PA, EPSTEIN JS: Inhibition of HIV replication by immunoliposomal antisense oligonucleotide. Antiviral Res. (1996) 33:11–20.
   PubMed Web of Science ®Google Scholar
• SLEPUSHKIN VA, SIM0ES S, DAZIN P et al.: Sterically stabilized pH-sensitive liposomes: Intracellular delivery of aqueous contents and prolonged circulation in viva j Biol. Chem. (1997) 272:2382–2388.
   Google Scholar
• •The authors report that the inclusion of PEG-PE in the membrane of pH-sensitive liposomes confers steric stability to these vesicles, thus prolonging their blood circulation. These liposomes delivered their aqueous contents into differentiated THP-1 cells in a pH-dependent manner. This formulation was used subsequently to mediate the delivery of antisense oligonudeotides against HIV-1 in human macrophages [68].
   Google Scholar
• ALLEN TM, HANSEN CB, GUO LSS: Subcutaneous administration of liposomes: A comparison with the intravenous and intraperitoneal routes of injection. Biochim. Biophys. Acta (1993) 1150:9–16.
   PubMed Web of Science ®Google Scholar
• PANTALEO G, GRAZIOSI C, DEMAREST JF et al: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (1993) 362:355–358.
   PubMed Web of Science ®Google Scholar
• PANTALEO G, FAUCI AS: New concepts in the immunopathogenesis of HIV infection. Ann. Rev Immunol. (1995) 13:487–512.
   PubMed Web of Science ®Google Scholar
• SCHEULE RK: The role of CpG motifs in immunostimulation and gene therapy. Adv. Drug Deify. Rev. (2000) 44:119–134.
   PubMed Web of Science ®Google Scholar
• HORNER AA, DATTA SK, TAKABAYASHI K et al: Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. Immunol (2001) 167:1584–1591.
   Web of Science ®Google Scholar
• MOSS RB, DIVELEY J, JENSEN FC, GOUVEIA E, SAVARY J, CARLO DJ: HIV-specific CD4(+) and CD8(+) immune responses are generated with a gp120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA. J. Interferon. Cytokine Res. (2000) 20:1131–1137.
   PubMed Web of Science ®Google Scholar
• SARVER N, CANTIN EM, CHANG PS etal.: Ribozymes as potential anti-HIV-1 therapeutic agents. Science (1990) 247:1222–1225.
   Google Scholar
• •The authors demonstrate that the expression of an anti-HIV-1 gag ribozyme reduces virus replication in HeLa CD4+ cells infected with HIV–1.
   Google Scholar
• ROSSI JJ, SARVER N: Catalytic antisense RNA (ribozymes): Their potential and use as anti-HIV-1 therapeutic agents. Adv. Exp. Med. Biol. (1992) 312:95–109.
   PubMedGoogle Scholar
• ZAIA JA, CHATTERJEE S, WONG la, ELKINS D, TAYLOR NR, ROSSI JJ: Status of ribozyme and antisense-based developmental approaches for anti-HIV-1 therapy. Ann. NY Acad. ScL (1992) 660:95–106.
   PubMed Web of Science ®Google Scholar
• ROSSI JJ, ELKINS D, ZAIA JA, SULLIVAN S: Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems. AIDS Res. Hum. Retroviruses (1992) 8:183–189.
   PubMed Web of Science ®Google Scholar
• MUOTRI AR, PEREIRA LD, VASQUES LD, MENCK CFM: Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function. Gene (1999) 237:303–310.
   PubMed Web of Science ®Google Scholar
• YU M, POESCHLA E, WONG-STAAL F: Progress towards gene therapy for HIV infection. Gene Ther. (1994) 1:13–26.
   PubMed Web of Science ®Google Scholar
• ROSSI JJ: Ribozyme therapy for HIV infection. Adv. Drug Deify. Rev (2000) 44:71–78.
   PubMed Web of Science ®Google Scholar
• CHANG PS, CANTIN EM, ZAIA JA et al.: Ribozyme-mediated site-specific cleavage of HIV-1 gene. Clin. Biotech. (1990) 2:23–31.
   Google Scholar
• •First demonstration that an anti-HIV-1 gag hammerhead ribozyme expressed in HeLa CD4+ cells is biologically active.
   Google Scholar
• VAISHNAV YN, WONG-STAAL F: The biochemistry of AIDS. Ann. Rev Biochem. (1991) 60:577–630.
   PubMed Web of Science ®Google Scholar
• •A review of the regions of the HIV genome that can be used as targets for ribozyme gene therapy.
   Google Scholar
• KIJIMA H, ISHIDA H, OHKAWA T, KASHANI-SABET M, SCANLON KJ: Therapeutic applications of ribozymes. Pharmacol Ther. (1995) 68:247–267
   PubMed Web of Science ®Google Scholar
• •A review of HIV sequences that can be used as targets for ribozyme gene therapy.
   Google Scholar
• DRAGIC T, LITWIN V, ALLAWAY GP et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 381:667–673.
   PubMed Web of Science ®Google Scholar
• FENG Y, BRODER CC, KENNEDY PE, BERGER EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G-protein-coupled receptor. Science (1996) 272:872–877.
   PubMed Web of Science ®Google Scholar
• GOILA R, BANERJEA AC: Sequence specific cleavage of the HIV-1 co-receptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: Inhibition of the co-receptor function by DNA-enzyme. FEBS Lett. (1998) 436:233–238.
   PubMed Web of Science ®Google Scholar
• GONZALEZ MA, SERRANO F, LLORENTE M, ABAD JL, GARCIA-ORTIZ MJ, BERNAD A: A hammerhead ribozyme targeted to the human chemokine receptor CCR5. Biochem. Biophys. Res. Commun. (1998) 251:592–596.
   PubMed Web of Science ®Google Scholar
• ••First demonstration of the inhibition ofthe expression of CCR5, a co-receptor for HIV-1, when a plasmid encoding a ribozyme targeted to CCR5 mRNA was co-transfected with the cCCR5 plasmid using lipoplexes.
   Google Scholar
• FENG Y, LEAVITT M, TRITZ R etal.: Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5. Virology (2000) 276:271–278.
   Google Scholar
• HEIDENREICH 0, PIEKEN W, ECKSTEIN F: Chemically modified RNA: approaches and applications. FASEB (1993) 7:90-96. 965 Expert Op/n. Biol. Ther. (2001) 1(6)
   Google Scholar
• CHRISTOFFERSEN RE, MARR JJ: Ribozymes as human therapeutic agents. J. Med. Chem. (1995) 38:2023–2037.
   PubMed Web of Science ®Google Scholar
• TAYLOR NR, KAPLAN BE, SWIDERSKI E LI H, ROSSI JJ: Chimeric DNA-RNA hammerhead ribozyme have enhanced in vitro catalytic efficiency and increased stability in vivo. Nucleic Acids Res. (1992) 17:4559–4565.
   Google Scholar
• MALONE RW, FELGNER PL, VERMA IM: Cationic liposome-mediated RNA transfection. Proc. Natl. Acad. Li. USA (1989) 86:6077–6081.
   PubMed Web of Science ®Google Scholar
• ROSSI JJ, CANTIN EM, SARVER N, CHANG PF: The potential use of catalytic RNAs in therapy of HIV infection and other diseases. Pharmacal. Ther. (1991) 50:245–254.
   PubMed Web of Science ®Google Scholar
• KONOPKA K, ROSSI JJ, SWIDERSKI E SLEPUSHKIN VA, DOZGLINES N: Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim. Biophys. Acta (1998) 1372:55–68.
   PubMed Web of Science ®Google Scholar
• •This paper demonstrates that in spite of the intracellular accumulation of cationic liposome-anti-HIV-1-ribozyme complexes, the inhibitory effect of the ribozyme on HIV-1 production in infected cells is negligible.
   Google Scholar
• BRAMLAGE B, LUZI E, ECKSTEIN F: HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture. Nucleic Acids Res. (2000) 28:4059–4067.
   PubMed Web of Science ®Google Scholar
• •This study utilises exogenous delivery of ribozymes for the inhibition of HIV-1 LTR-driven luciferase expression.
   Google Scholar
• KARIKO K, MEGYERI K, XIAO Q, BARNATHAN ES: Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA. FEBS Lett. (1994) 352:41-44. ma SNYDER DS, WU Y, WANG JL al.: Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood (1993) 82:600-605. Dm. LEOPOLD LH, SHORE SK, NEWKIRK TA, REDDY RMV, REDDY EP: Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood (1995) 85:2162–2170.
   Google Scholar
• KIEHNTOPF M, BRACH MA, LICHT T et al.: Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO (1994) 13:4645–4652.
   PubMed Web of Science ®Google Scholar
• GU J-L, VEERAPANANE D, ROSSI J, NATARAJAN R, THOMAS L, NADLER J: Ribozyme-mediated inhibition of expression of leukocyte-type 12-lipoxygenase in porcine aortic vascular smooth muscle cells. Circ. Res. (1995) 77:14–20.
   PubMed Web of Science ®Google Scholar
• WELCH PJ, BARBER JR, WONG-STAAL F: Expression of ribozymes in gene transfer systems to modulate target RNA levels. Cum: Opin. Biatechnol. (1998) 9:486–496.
   PubMed Web of Science ®Google Scholar
• ARNDT GM, RANK GH: Co-localization of antisense RNAs and ribozymes with their target mRNAs. Cenome (1997) 40:785–797.
   Google Scholar
• BERTRAND E, CASTANOTTO D, ZHOU C et al.: The expression cassette determines the functional activity of ribozyme in mammalian cells by controlling their intracellular localization. RIVA (1997) 3:75–88.
   Google Scholar
• HOWES R, HOMANN M, OELZE I et al.: The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells. Nucleic Acids Res. (1997) 24:769-775. ma. CAMERON FH, JENNINGS PA: Multiple domains in a ribozyme construct confer increased suppressive activity in monkey cells. Antisense Res. Dev. (1994) 4:87–95.
   Google Scholar
• KONOPKA K, LEE NS, ROSSI J, DOZGLINES N: Rev-binding aptamer and CMV promoter act as decoys to inhibit HIV replication. Gene (2000) 255:235–244.
   PubMed Web of Science ®Google Scholar
• •The authors show that the strong enhancer/promoter CMV severely suppresses the expression of the HIV-1 proviral DNA even when it is not transcribing an anti-HIV-1 construct.
   Google Scholar
• THOMPSON JD, AYERS DF, MALMSTROM TA et al.: Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. Nucleic Adds Res. (1995) 23:2259–2268.
   PubMed Web of Science ®Google Scholar
• GOOD PD, KROKOS AJ, LI SXL et al.: Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther. (1997) 4:45–54.
   PubMed Web of Science ®Google Scholar
• ••This paper demonstrates the role ofsequences appended to Pol III transcripts in intracellular localisation of these transcripts.
   Google Scholar
• SUN LQ, WARRILOW D, WANG L, WITHERINGTON C, MACPHERSON J, SYMONDS G: Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus Type I replication in permissive cell lines. Proc. Natl. Acad. Sci. USA (1994) 91:9715–9719.
   PubMed Web of Science ®Google Scholar
• SUN LQ, WANG L, GERLACH WL, SYMONDS G: Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Nucleic Acids Res. (1995) 23:2909–2913.
   PubMed Web of Science ®Google Scholar
• MICHIENZI A, CONTI L, VARANO B, PRISLEI S, GESSANI S, BOZZONI I: Inhibition of human immunodeficiency virus Type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line. Hum. Gene Ther. (1998) 9:621–628.
   PubMed Web of Science ®Google Scholar
• YAMADA 0, KRAUS G, LUZNIK L, YU M, WONG-STAAL F: A chimeric human immunodeficiency virus Type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J. Viral. (1996) 70:1596–1601.
   PubMed Web of Science ®Google Scholar
• OJWANG JO, HAMPEL A, LOONEY DJ, WONG-STAAL F, RAPPAPORT J: Inhibition of human immunodeficiency virus Type 1 expression by a hairpin ribozyme. Proc. Natl. Acad. Sci. USA (1992) 89:10802–10806.
   PubMed Web of Science ®Google Scholar
• YU M, OJWANG J, YAMADA 0 et al.: A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus Type 1. Proc. Nati Acad. Sci. USA (1993) 90:6340–6344.
   Google Scholar
• CHEN C-J, BANERJEA AC, HARMISON GG, HAGLUND K, SCHUBERT M: Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication - Potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res. (1992) 20:4581–4589.
   PubMed Web of Science ®Google Scholar
• KONOPKA K, DOZGLJNES N, ROSSI J, LEE NS: Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev binding aptamer and ribozyme DNAs. J. Drug Targeting (1998) 5:247–259.
   PubMed Web of Science ®Google Scholar
• CHENG PW: Receptor ligand-facilitated gene transfer: Enhancement of liposome-mediated gene transfer and expression by transferrin. Hum. Gene Ther. (1996) 7:275–282.
   PubMed Web of Science ®Google Scholar
• SIM ()ES S, SLEPUSHKIN V, GASPAR R, PEDROSO DE LIMA MC, DOZGLINES N: Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic
   Google Scholar
• ••peptides. Gene Ther. (1998) 5:955–964.
   Google Scholar
• TRAPNELL BC, GORZIGLIA M: Gene therapy using adenoviral vectors. Cun: Opin. Biatechrial (1994) 5:617–625.
   PubMedGoogle Scholar
• SIN GHAL A, HUANG L. Gene transfer in mammalian cells using liposomes as carriers. In: Gene Therapeutics: Methods and Applications of Diirct Gene Transfer Wolf JA (Ed.), Birkhäuser, Boston (1994):118–142.
   Google Scholar
• CLARK PR, HERSH EM: Cationic lipid-mediated gene transfer: Current concepts. Curr. Opin. Mal. Therapeut. (1999) 1:158–176.
   PubMed Web of Science ®Google Scholar
• TEMPLETON NS, LASIC DD: New directions in liposome gene delivery. Mal Biatechnol (1999) 11:175–180.
   PubMed Web of Science ®Google Scholar
• DOZGLINES N, SIMOES S, PIRES P, PEDROSO DE LIMA MC: Gene delivery by cationic lipid-DNA complexes. In: Polymeric Biamaterials. Dumitriu S (Ed.), Marcel Dekker, New York (2001) (In Press).
   Google Scholar
• LASIC DD, TEMPLETON NS: Liposomes in gene therapy. Adv. Drug Deify. Rev. (1996) 20:221–266.
   Web of Science ®Google Scholar
• BALLY MB, HARVIE P, WONG FMP, KONG S, WASAN EK, REIMER DL: Biological barriers to cellular delivery of lipid-based DNA carriers. Adv. Drug Deily. Rev (1999) 38:291–315.
   PubMed Web of Science ®Google Scholar
• TROS DE ILARDUYA C, DOZGLINES N: Efficient gene transfer by transferrin lipoplexes in the presence of serum. Biochim. Biophys. Acta (2000) 1463:333–342.
   PubMed Web of Science ®Google Scholar
• •This study demonstrates the ability of transferrin-lipoplexes to transfect cells even in the presence of 60% serum.
   Google Scholar
• SIMOES S, SLEPUSHKIN V, PIRES P, GASPAR R, PEDROSO DE LIMA MC, DOZGLINES N: Human serum albumin enhances DNA transfection by lipoplexes and confers resistance to inhibition by serum. Biochim. Biophys. Acta (2000) 1463:459–469.
   PubMed Web of Science ®Google Scholar
• ••The authors describe the use of humanserum albumin to enhance gene transfer to various cell lines and primary macrophages, and to mediate serum-resistant transfection. They also show that the combination of a pH-sensitive peptide and albumin results in higher transfection of macrophages.
   Google Scholar
• SCHEULE RK, ST.GEORGE JA, BAGLEY RG et al.: Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum. Gene Ther. (1997) 8:689–707.
   Google Scholar
• LIU F, QI H, HUANG L, LIU D: Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration. Gene Ther. (1997) 4:517–523.
   PubMed Web of Science ®Google Scholar
• ZHU N, LIGGITT D, LIU Y, DEBS R: Systemic gene expression after intravenous DNA delivery into adult mice. Science (1993) 261:209–211.
   PubMed Web of Science ®Google Scholar
• SAEKI Y, WATAYA-KANEDA M, TANAKA K, KANEDA Y: Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ liposomes. Gene Ther. (1998) 5:1031–1037.
   PubMed Web of Science ®Google Scholar
• TU G, KIRCHMAIER AL, LIGGITT D et al.: Non-replicating Epstein-Barr virus-based plasmids extend gene expression and can improve gene therapy in vivo. j Biol. Chem. (2000) 275:30408–30414.
   PubMed Web of Science ®Google Scholar
• OTOMO T, YAMAMOTO S, MORISHITA R, KANEDA Y: EBV replicon vector system enhances transgene expression in vivo: applications to cancer gene therapy. J Gene Med. (2001) 3:345–352.
   PubMed Web of Science ®Google Scholar
• ANDERSON WF: Human gene therapy. Science (1992) 256:808–813.
   PubMed Web of Science ®Google Scholar
• •This review describes and predicts future use of viral vectors for human gene therapy.
   Google Scholar
• MILLER AD: Human gene therapy comes of age. Nature (1992) 357:455–460.
   PubMed Web of Science ®Google Scholar
• •This article describes and predicts future use of viral vectors for human gene therapy.
   Google Scholar
• NALDINI L, BLOMER U, GALLAY P et al.: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 272:263–267.
   PubMed Web of Science ®Google Scholar
• ••Describes the rationale behind the use ofHIV-based vectors for infection of quiescent cells.
   Google Scholar
• NALDINI L, VERMA IM: Lentiviral vectors. Adv.Virus Res. (2000) 55:599–609.
   PubMed Web of Science ®Google Scholar
• CURRAN MA, KAISER SM, ACHACOSO PL, NOLAN GP: Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mal Ther. (2000) 1:31–38.
   PubMed Web of Science ®Google Scholar
• POESCHLA EM, WONG-STAAL F, LOONEY DJ: Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nature Med. (1998) 4:354–357.
   PubMed Web of Science ®Google Scholar
• WHITE SM, RENDA M, NAM NY et al.: Lentivirus vectors using human and simian immunodeficiency virus elements.j Viral. (1999) 73:2832–2840.
   PubMed Web of Science ®Google Scholar
• BERKNER KL: Expression of heterologous sequences in adenoviral vectors. Curr. Top. Microbial Immune]. (1992) 158:39–66.
   PubMed Web of Science ®Google Scholar
• •Describes rationale for and early designs of adenovirus-based vectors.
   Google Scholar
• SMITH TA, MEHAFFEY MG, KAYDA DB et al.: Adenovirus mediated expression of therapeutic plasma levels of human Factor IX in mice. Nature Genet. (1993) 5:397–402.
   PubMed Web of Science ®Google Scholar
• LI Q, KAY MA, FINEGOLD M, STRATFORD-PERRICAUDET LD, WOO SL: Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. (1993) 4:403–409.
   PubMed Web of Science ®Google Scholar
• BRIAND P, KAHN A: Values and limits of adenoviral vectors for gene transfer in vivo. Pathal Biol. (Paris) (1993) 41:663–671.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN SK, COLLIS P, HERMONAT PL, MUZYCZKA N: Adeno-associated virus general transduction vectors: analysis of proviral structures.j Viral. (1988) 62:1963–1973.
   Google Scholar
• HERMONAT PL, MUZYCZKA N: Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc. Natl. Acad. Li.. USA (1984) 81:6466–6470.
   PubMed Web of Science ®Google Scholar
• •One of the first descriptions of novel properties of AAV for use as a gene delivery vehicle.
   Google Scholar
• ROLLING F, SAMULSKI RJ: AAV as a viral vector for human gene therapy. Generation of recombinant virus. Mal Biatechnol (1995) 3:9–15.
   Google Scholar
• CHIRICO J, TREMPE JP: Optimization of packaging of adeno-associated virus gene therapy vectors using plasmid transfections. Viral. Methods (1998) 76:31–41.
   PubMed Web of Science ®Google Scholar
• PODSAKOFF G, WONG la, CHATTERJEE S: Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors.j Viral. (1994) 68:5656–5666.
   PubMed Web of Science ®Google Scholar
• CHATTERJEE S, LI W, WONG CA et al: Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. Blood (1999) 93:1882–1894.
   PubMed Web of Science ®Google Scholar
• KRISKY DM, MARCONI PC, OLIGINO TJ et al: Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications.
   Google Scholar
• •• Gene Ther. (1998) 5:1517–1530.
   Google Scholar
• MARCONI P, SIMONATO M, ZUCCHINI S et al.: Replication-defective herpes simplex virus vectors for neurotrophic factor gene transfer in vitro and in vivo. Gene Ther. (1999) 6:904–912.
   PubMed Web of Science ®Google Scholar
• GOINS WF, KRISKY D, MARCONI P et al.: Herpes simplex virus vectors for gene transfer to the nervous system. J. Neurovirol. (1997) 3\(Suppl. 1):S80–S88.
   Google Scholar
• STRAYER DS: Gene therapy using 5V40-derived vectors: what does the future hold? J. Cell Physiol. (1999) 181:375–384.
   Web of Science ®Google Scholar
• WALTHER W, STEIN U: Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs (2000) 60:249–271.
   PubMed Web of Science ®Google Scholar
• TAL J: Adeno-associated virus-based vectors in gene therapy. J. Biomed. Sci. (2000) 7:279–291.
   PubMed Web of Science ®Google Scholar
• ALEMANY R, BALAGUE C, CURIEL DT: Replicative adenoviruses for cancer therapy. Nat. Biatechnol. (2000) 18:723–727.
   PubMed Web of Science ®Google Scholar
• PALU G, PAROLIN C, TAKEUCHI Y, PIZZATO M: Progress with retroviral gene vectors. Rev Med. Viral. (2000) 10:185–202.
   PubMed Web of Science ®Google Scholar
• FINK DJ, DELUCA NA, YAMADA M, WOLFE DE GLORIOSO JC: Design and application of HSV vectors for neuroprotection. Gene Ther. (2000) 7:115–119.
   PubMed Web of Science ®Google Scholar
• STONE D, DAVID A, BOLOGNANI E LOWENSTEIN PR, CASTRO MG: Viral vectors for gene delivery and gene therapy within the endocrine system. J. Endocrinal. (2000) 164:103.
   PubMed Web of Science ®Google Scholar
• MIHALY J, HOGGA I, BARGES S et al.: Chromatin domain boundaries in the Bithorax complex. Cell. Mai Life Sci. (1998) 54:60–70.
   PubMed Web of Science ®Google Scholar
• GLAZKOV MV: Boundaries of structure-functional units (domains) of eukaryotic chromosomes. Genetika (1998) 34:593–604.
   PubMedGoogle Scholar
• WOLFE AP: Gene regulation. Insulating chromatin. Curr. Biol. (1994) 4:85–87.
   PubMedGoogle Scholar
• ZHONG XP, KRANGEL MS: An enhancer-blocking element between alpha and delta gene segments within the human T cell receptor alpha/delta locus. Proc. Nati Acad. Sci. USA (1997) 94:5219–5224.
   PubMed Web of Science ®Google Scholar
• CHUNG JH, WHITELEY M, FELSENFELD G: A 5' element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell (1993) 74:505–514.
   PubMed Web of Science ®Google Scholar
• RIVELLA S, CALLEGARI JA, MAY C, TAN CW, SADELAIN M: The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J. Viral. (2000) 74:4679–4687.
   PubMed Web of Science ®Google Scholar
• STEINWAERDER DS, LIEBER A: Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Ther. (2000) 7:556–567.
   PubMed Web of Science ®Google Scholar
• EMERY DW, STAMATOYANNOPOULOS G: Stem cell gene therapy for the beta-chain hemoglobinopathies. Problems and progress. Ann. NY Acad. Li. (1999) 872:94–107.
   PubMed Web of Science ®Google Scholar
• RIVELLA S, SADELAIN M: Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. Semin. Hen-iota (1998) 35:112–125.
   PubMed Web of Science ®Google Scholar
• NEFF T, SHOTKOSKI F, STAMATOYANNOPOULOS G: Stem cell gene therapy, position effects and chromatin insulators. Stem Cells (1997) 15:265–271.
   PubMed Web of Science ®Google Scholar
• CHUNG JH, BELL AC, FELSENFELD G: Characterization of the chicken beta-globin insulator. Proc. Nati Acad. Sci. USA (1997) 94:575–580.
   PubMed Web of Science ®Google Scholar
• ••First thorough characterisation offunctional limits of the vertebrate insulator. This is a paper well worth reading.
   Google Scholar
• KALOS M, FOURNIER RE: Position-independent transgene expression mediated by boundary elements from the apolipoprotein B chromatin domain. Mai Cell Biol. (1995) 15:198–207.
   PubMed Web of Science ®Google Scholar
• KLEHR D, SCHLAKE T, MAASS K, BODE J: Scaffold-attached regions (SAR elements) mediate transcriptional effects due to butyrate. Biochem. (1992) 31:3222–3229.
   PubMed Web of Science ®Google Scholar
• POLJAK L, SEUM C, MATTIONI T, LAEMMLI UK: SARs stimulate but do not confer position independent gene expression. Nucleic Acids Res. (1994) 22:4386–4394.
   PubMed Web of Science ®Google Scholar
• AGARWAL M, AUSTIN TW, MOREL F, CHEN J, BOHNLEIN E, PLAVEC I: Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J. Viral. (1998) 72:3720–3728.
   PubMed Web of Science ®Google Scholar
• SHIMIZU Y, OKAY, OGAWA H, KISHIMOTO T, SUGIYAMA H: Regulation of Thy-1 gene expression by the methylation of the 5' region of Thy-1 gene and intracellular regulatory factors in immature B cells. Immunal. Invest. (1992) 21:183–191.
   PubMed Web of Science ®Google Scholar
• SZYF M, TANIGAWA G, McCARTHY PLJR: A DNA signal from the Thy-1 gene defines de novo methylation patterns in embryonic stem cells. Mai Cell Biol. (1990) 10:4396–4400.
   PubMed Web of Science ®Google Scholar
• RYU WS, MERTZ JE: Simian virus 40 late transcripts lacking excisable intervening sequences are defective in both stability in the nucleus and transport to the cytoplasm. J. Viral. (1989) 63:4386–4394.
   PubMed Web of Science ®Google Scholar
• HUANG MT, GORMAN CM: Intervening sequences increase efficiency of RNA 3' processing and accumulation of cytoplasmic RNA. Nucleic Acids Res. (1990) 18:937–947.
   PubMed Web of Science ®Google Scholar
• ••An excellent study demonstrating that anintron located in the 5' untranslated region of a CAT cDNA coding sequence dramatically increases the levels of poly A+ cytoplasmic RNA as wells as protein product.
   Google Scholar
• MATSUMOTO K, WASSARMAN KM, WOLFFE AP: Nuclear history of a pre-mRNA determines the translational activity of cytoplasmic mRNA. EMBO J. (1998) 17:2107–2121.
   PubMed Web of Science ®Google Scholar
• ••This study demonstrates that the nuclearhistory of a transcript decides its cytoplasmic fate, and describes the importance of the placement of the intron in a cDNA sequence to obtain optimal nuclear to cytoplasmic transport.
   Google Scholar
• SHI ST, HUANG P, LI HP, LAI MM: Heterogeneous nuclear ribonucleoprotein Al regulates RNA synthesis of a cytoplasmic virus. EMBO J. (2000) 19:4701–4711.
   PubMed Web of Science ®Google Scholar
• BRODSKY AS, SILVER PA: Pre-mRNA processing factors are required for nuclear export. RNA (2000) 6:1737–1749.
   PubMedGoogle Scholar
• MAUTINO MR, KEISER N, MORGAN RA: Improved titers of HIV-based lentiviral vectors using the SRV-1 constitutive transport element. Gene Ther. (2000) 7:1421–1424.
   PubMed Web of Science ®Google Scholar
• SCHAMBACH A, WODRICH H, HILDINGER M, BOHNE J, KRAUSSLICH HG, BAUM C: Context dependence of different modules for
   Google Scholar